Mathew Bogart, APRN
Family · Summerville, SCNPI 1508320086
Payments from drug & device makers
Across 133 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$257
- Lilly USA, LLC$212
- AstraZeneca$192
- Sanofi-aventis U.S. LLC$177
- Corcept Therapeutics$169
- Novo Nordisk$158
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 10 | $257 |
| Lilly USA, LLC | 16 | $212 |
| AstraZeneca | 12 | $192 |
| Sanofi-aventis U.S. LLC | 5 | $177 |
| Corcept Therapeutics | 11 | $169 |
| Novo Nordisk | 8 | $158 |
| Mannkind Corporation | 8 | $156 |
| AbbVie | 12 | $136 |
| Boehringer Ingelheim | 6 | $112 |
| Nestle Healthcare Nutrition Inc. | 4 | $89 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| Esperion Therapeutics, Inc. | 4 | $58 |
| Radius Health, Inc. | 3 | $57 |
| Antares Pharma, Inc. | 3 | $43 |
| Boston Scientific | 2 | $39 |
| Recordati_rare_diseases_inc. | 1 | $39 |
| Vifor Pharma, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $36 |
| Bayer | 2 | $35 |
| Merck | 2 | $31 |
| IBSA Pharma Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $28 |
| Tandem Diabetes Care, Inc. | 1 | $27 |
| Amgen | 2 | $27 |
| Amneal Pharmaceuticals LLC | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$120
How this compares
$2,355 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 256 | $415,385 |
| FarxigaDapagliflozin Propanediol | 224 | $216,869 |
| JardianceEmpagliflozin | 176 | $190,553 |
| MounjaroTirzepatide | 123 | $176,700 |
| TrulicityDulaglutide | 74 | $93,662 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 58 | $70,757 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $38,403 |
| Humalog Kwikpen U-100Insulin Lispro | 77 | $24,127 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $20,067 |
| Novolog FlexpenInsulin Aspart | 90 | $17,822 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $17,315 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $16,592 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $16,265 |
| Repatha SureclickEvolocumab | 11 | $14,952 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 108 | $14,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $158 | $426,488288 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $212 | $273,249212 claims |
| AstraZenecaFarxiga | $192 | $216,869224 claims |
| Boehringer IngelheimJardiance | $112 | $190,553176 claims |
| Sanofi-aventis U.S. LLCLantus | $177 | $2,87818 claims |
| AbbVieSynthroid | $136 | $2,27240 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $25 | $1,381147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.
Other family in Summerville
- Karen McKerihanSummerville$54K
- Allison PlasterSummerville$11K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.